Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26831413
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26831413
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Indian+J+Med+Res
2015 ; 142
(6
): 647-54
Nephropedia Template TP
Indian J Med Res
2015[Dec]; 142
(6
): 647-54
PMID26831413
show ga
Ever since the introduction of the first disease modifying therapies, the concept
of multiple sclerosis treatment algorithms developed ceaselessly. The increasing
number of available drugs is paralleled by impelling issue of ensuring the most
appropriate treatment to the right patient at the right time. The purpose of this
review is to describe novel agents recently approved for multiple sclerosis
treatment, namely teriflunomide, alemtuzumab and dimethylfumarate, focusing on
mechanism of action, efficacy data in experimental setting, safety and
tolerability. The place in therapy of newer treatment implies careful balancing
of risk-benefit profile as well as accurate patient selection. Hence the widening
of therapeutic arsenal provides greater opportunity for personalized therapy but
also entails a complex trade-off between efficacy, tolerability, safety and
eventually patient preference.
|Antibodies, Monoclonal/adverse effects/*therapeutic use
[MESH]
free
free
free
